Stock Watch: Biotechs Sell The Family Silver
But Are They Just Delaying The Inevitable?
When loss-making biotech companies mix debt with sluggish sales, difficult options like restructuring and asset sales remain.
When loss-making biotech companies mix debt with sluggish sales, difficult options like restructuring and asset sales remain.